Table 1 Characteristics of trials included in meta-analyses
STOP-NIDDM (n = 1429) | Voglibose Ph-3 (n = 1778) | ABC (n = 859) | ACE (n = 6522) | UKPDS (n = 1946) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Year published | 2002 | 2009 | 2017 | 2017 | 1998 | |||||
Recruitment dates | December 1995–July 1998 | October 2003–March 2007 | May 2005–June 2012 | March 2009–October 2015 | May 1994–September 1994 | |||||
Dose | 100 mg three times daily | 0.2 mg three times daily | 0.2 mg three times daily | 50 mg three times daily | 100 mg three times daily | |||||
Inclusion criteria | Impaired glucose tolerance | Impaired glucose tolerance | Impaired glucose tolerance and previous MI | Impaired glucose tolerance and established coronary heart disease | N/A | |||||
Cardiovascular outcome | Coronary heart diseasea, CVD death, congestive heart failure, cerebrovascular events and peripheral vascular disease | N/A | CVD composite endpointb | MACE- 5c | MACE-5c | |||||
Diabetes outcome | New-onset diabetes | New-onset diabetes | N/A | New-onset diabetes | N/A | |||||
Acarbose (n = 714) | Placebo (n = 715) | Voglibose (n = 897) | Placebo (n = 881) | Voglibose (n = 424) | Placebo (n = 435) | Acarbose (n = 3272) | Placebo (n = 3250) | Acarbose (n = 973) | Placebo (n = 973) | |
|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 54.3 ± 7.9 | 54.6 ± 7.9 | 55.7 ± 9.1 | 55.7 ± 9.2 | 67 (57, 73) | 65 (58, 73) | 64.4 ± 8.2 | 64.3 ± 8.0 | 60 ± 9 | 60 ± 9 |
BMI (Kg/m2) | 31.0 ± 4.3 | 30.9 ± 4.2 | 25.8 ± 3.7 | 25.9 ± 3.8 | 24.2 (22.5, 26.0) | 24.3 (22.5,26.3) | 25.3 ± 3.1 | 25.5 ± 3.1 | 29.8 ± 5.6 | 29.6 ± 5.7 |
Female | 353 (52%) | 342 (50%) | 356 (40%) | 351 (40%) | 60 (14.2%) | 58 (13.3%) | 877 (27%) | 885 (27%) | 369 (37.9%) | 344 (35.4%) |